Key Highlights

  • AEON Biopharma shares closed up 26% at $0.29.
  • The company reported pilot forced-degradation data for ABP-450.
  • The data showed comparable thermal potency-loss and oxidative-stress patterns to BOTOX.
  • A multi-lot comparability study is expected to begin in the first half of 2027.

AEON Biopharma, Inc. (NYSE: AEON) shares closed up 26% at $0.29 after the company reported pilot forced-degradation data showing ABP-450 had comparable thermal potency-loss and oxidative-stress patterns to BOTOX.

What Happened

The data adds analytical support for AEON's planned 351(k) biosimilar pathway, though formal conclusions depend on a multi-lot comparability study expected to begin in the first half of 2027.

Market Reaction

Shares rose as investors responded to the supportive comparability data, viewing it as an incremental step toward validating ABP-450's biosimilar pathway relative to BOTOX.

Outlook

The planned multi-lot comparability study, expected to begin in the first half of 2027, represents the next major disclosed milestone supporting ABP-450's 351(k) biosimilar pathway.